Clinical Trial Update: Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

View source ↗

Summary

This clinical trial update notes that mosunetuzumab is being evaluated in a compassionate-use program for relapsed/refractory follicular lymphoma after at least…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: Andrés José Maria Ferreri | Conditions: Relapsed/Refractory Follicular Lymphoma | Status: RECRUITING